Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

Terry Silimanis and his sister, Elaine Makos, attended chemotherapy appointments at Markham Stouffville Hospital in 2024. Like many people, Terry Silimanis tried to ignore the physical discomfort he ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

Ovarian Cancer Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn) U.S. About is the world's leading source for international market research reports and market data. We provide you ...

Adjuvant chest wall irradiation should be omitted in most patients meeting the eligibility criteria for SUPREMO,” said Ian Kunkler, MB BChir.

In this systematic review, ten studies reported risk reclassification of prostate cancer with genome classifier testing, with ...

Chandigarh: The PGI's nuclear medicine department has been waiting for over eight months for the Union ministry's approval to ...

Neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to better survival outcomes ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...